{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:09Z","timestamp":1788923889303,"version":"build-2803163510"},"reference-count":43,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.2169\/internalmedicine.4235-24","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T18:10:50Z","timestamp":1724782250000},"page":"32-40","source":"Crossref","is-referenced-by-count":1,"title":["CAR-T Therapy Can Be a Useful Treatment Modality for More Than Just Hematologic Malignancies"],"prefix":"10.2169","volume":"65","author":[{"given":"Kazuhiro","family":"Ikegame","sequence":"first","affiliation":[{"name":"Hematopoietic Cell Transplantation Center, Aichi Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Taylor PA, Ehrhardt MJ, Roforth MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 109: 1307-1315, 2007.","DOI":"10.1182\/blood-2006-05-022772"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hosen N, Matsunaga Y, Hasegawa K, et al. The activated conformation of integrin \u03b2<sub>7<\/sub> is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med 23: 1436-1443, 2017.","DOI":"10.1038\/nm.4431"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wang JY, Wang L. CAR-T cell therapy: where are we now, and where are we heading? Blood Sci 5: 237-248, 2023.","DOI":"10.1097\/BS9.0000000000000173"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lickefett B, Chu L, Ortiz-Maldonado V, et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14: 1303935, 2023.","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"5","unstructured":"5. Vinnakota JM, Biavasco F, Schwabenland M, et al. Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer. Forthcoming."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Han J, Zhang B, Zheng S, Jiang Y, Zhang X, Mao K. The progress and prospects of immune cell therapy for the treatment of cancer. Cell Transplant 33: 9636897241231892, 2024.","DOI":"10.1177\/09636897241231892"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603: 934-941, 2022.","DOI":"10.1038\/s41586-022-04489-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M<sup>+<\/sup> diffuse midline gliomas. Nat Med 24: 572-579, 2018.","DOI":"10.1038\/s41591-018-0006-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zhang Y, Zhang Z, Ding Y, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J Cancer Res Clinical Oncol 147: 3725-3734, 2021.","DOI":"10.1007\/s00432-021-03613-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28: 1189-1198, 2022.","DOI":"10.1038\/s41591-022-01800-8"},{"key":"11","doi-asserted-by":"crossref","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"11. Wang Y, Chen M, Wu Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology 7: e1440169, 2018.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy 22: 573-580, 2020.","DOI":"10.1016\/j.jcyt.2020.04.088"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Feng K, Liu Y, Guo Y, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 9: 838-847, 2018.","DOI":"10.1007\/s13238-017-0440-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pang N, Shi J, Qin L, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol 14: 118, 2021.","DOI":"10.1186\/s13045-021-01128-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Rojas-Quintero J, D\u00edaz MP, Palmar J, et al. Car T cells in solid tumors: overcoming obstacles. Int J Mol Sci 25: 4170, 2024.","DOI":"10.3390\/ijms25084170"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int 24: 133, 2024.","DOI":"10.1186\/s12935-024-03315-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yuan G, Ye M, Zhang Y, Zeng X. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors. Med Oncol 41: 126, 2024.","DOI":"10.1007\/s12032-024-02310-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Najafi S, Mortezaee K. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: a focus on anti PD-1\/PD-L1 antibodies. Life Sci 338: 122387, 2024.","DOI":"10.1016\/j.lfs.2023.122387"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004.","DOI":"10.1056\/NEJMoa032534"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222-233, 2010.","DOI":"10.1002\/art.27233"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69: 409-412, 2010.","DOI":"10.1136\/ard.2009.109041"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385: 567-569, 2021.","DOI":"10.1056\/NEJMc2107725"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mackensen A, M\u00fcller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28: 2124-2132, 2022.","DOI":"10.1038\/s41591-022-02017-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390: 687-700, 2024.","DOI":"10.1056\/NEJMoa2308917"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet 402: 2034-2044, 2023.","DOI":"10.1016\/S0140-6736(23)01126-1"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. M\u00fcller F, Boeltz S, Knitza J, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401: 815-818, 2023.","DOI":"10.1016\/S0140-6736(23)00023-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pecher AC, Hensen L, Klein R, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329: 2154-2162, 2023.","DOI":"10.1001\/jama.2023.8753"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bergmann C, M\u00fcller F, Distler JHW, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82: 1117-1120, 2023.","DOI":"10.1136\/ard-2023-223952"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Granit V, Benatar M, Kurtoglu M, et al.; MG-001 Study Team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol 22: 578-590, 2023.","DOI":"10.1016\/S1474-4422(23)00194-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther 8: 5, 2023.","DOI":"10.1038\/s41392-022-01278-3"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Johnson NM, Koumpouras F. Chimeric antigen receptors: &quot;CARs&quot; in the fast lane for rheumatology. Curr Opin Rheumatol 36: 176-183, 2024.","DOI":"10.1097\/BOR.0000000000001012"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Daamen AR, Lipsky PE. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease. Ann Rheum Dis 83: 696-699, 2024.","DOI":"10.1136\/ard-2024-225638"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Chasov V, Zmievskaya E, Ganeeva I, et al. Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies. Antibodies (Basel) 13: 2024.","DOI":"10.3390\/antib13010010"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Eichholz K, Fukazawa Y, Peterson CW, et al. Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4<sup>+<\/sup> T cells in germinal centers. J Clin Invest 134: e169309, 2024.","DOI":"10.1172\/JCI169309"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nasiri-Jahrodi A, Barati M, Namdar Ahmadabad H, Badali H, Morovati H. A comprehensive review on the role of T cell subsets and CAR-T cell therapy in <i>Aspergillus fumigatus<\/i> infection. Hum Immunol 85: 110763, 2024.","DOI":"10.1016\/j.humimm.2024.110763"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kumaresan PR, Wurster S, Bavisi K, et al. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting <i>Aspergillus fumigatus<\/i>. mBio 15: e0341323, 2024.","DOI":"10.1128\/mbio.03413-23"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Su H, Anthony-Gonda K, Orentas RJ, Dropuli\u0107 B, Goldstein H. Generation of anti-HIV CAR-T cells for preclinical research. Methods Mol Biol 2807: 287-298, 2024.","DOI":"10.1007\/978-1-0716-3862-0_20"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mao Y, Liao Q, Zhu Y, et al. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov 10: 49, 2024.","DOI":"10.1038\/s41421-024-00658-z"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kumaresan PR, Manuri PR, Albert ND, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA 111: 10660-10665, 2014.","DOI":"10.1073\/pnas.1312789111"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Shu J, Xie W, Chen Z, Offringa R, Hu Y, Mei H. The enchanting canvas of CAR technology: unveiling its wonders in non-neoplastic diseases. Med 5: 495-529, 2024.","DOI":"10.1016\/j.medj.2024.03.016"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Skuljec J, Chmielewski M, Happle C, et al. Chimeric antigen receptor-redirected regulatory t cells suppress experimental allergic airway inflammation, a model of asthma. Front Immunol 8: 1125, 2017.","DOI":"10.3389\/fimmu.2017.01125"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Choe JH, Yu T, Abramson JS, Abou-El-Enein M. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv 8: 484-496, 2024.","DOI":"10.1182\/bloodadvances.2023011793"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Thavorn K, Thompson E, Kumar S, et al. Economic evaluations of CAR-T cell therapies for hematologic and solid malignancies: a systematic review. Value Health 27: 1149-1173, 2024.","DOI":"10.1016\/j.jval.2024.04.004"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_4235-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:26:28Z","timestamp":1767410788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/1\/65_4235-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4235-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"4235-24"}}